Methylene Blue Treatment in Refractory Shock Following Chemotherapy: A Case Report (2025)

Peer-Reviewed Study · Goyushova A; Ahmadova N; Aliyev I · June 22, 2025

Goyushova A et al., 2025-06-22: Case report of a 68-year-old man with metastatic prostate adenocarcinoma who developed vasoplegic shock after docetaxel and improved rapidly after intravenous methylene blue, with normalisation of lactate and recovery of renal and respiratory function.

We report the case of a 68-year-old male with metastatic prostate adenocarcinoma who developed refractory shock shortly after receiving docetaxel chemotherapy.

Goyushova A et al., 2025-06-22: Case report of a 68-year-old man with metastatic prostate adenocarcinoma who developed vasoplegic shock after docetaxel and improved rapidly after intravenous methylene blue, with normalisation of lactate and recovery of renal and respiratory function. Study type: single case report. N=1. Country: Azerbaijan. Dose/route: intravenous methylene blue, dose per full text. Comparator: none. Other treatment: docetaxel chemotherapy; maximal vasopressors and steroids had failed before methylene blue. Outcome: rapid haemodynamic improvement, lactate normalisation, renal and respiratory recovery. Funder/conflicts: per full text. This is methylene blue for a complication of cancer treatment, not for the cancer itself, and it is the only prostate-cancer-linked human document in this run. Study type: case report.